Success In Kadimastem’s First Pre-Clinical Trial For Treatment Of Amyotrophic Lateral Sclerosis (ALS)

NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem (TASE: KDST) reported success in a preclinical trial for the treatment of ALS.

ALS is the most serious of a group of degenerative diseases that damage the motor neurons, which control most of the muscles in the body. The destruction of these neurons causes complete paralysis of the muscles they control. There is no cure or any significant drug treatment today for ALS. In recent years, there has been growing scientific evidence that in patients with the disease, the ability of the central nervous system’s support cells (astrocytes) to maintain a growth environment that supports the motor neurons is impaired. Injecting healthy, functioning support cells into the nervous system of ALS patients could provide systemic support for the damaged motor neurons and thereby slow the progression of the disease, improve patients’ quality of life, and extend their lives.

Help employers find you! Check out all the jobs and post your resume.